| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/19/2002 | WO2002072609A2 Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
| 09/19/2002 | WO2002072608A2 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
| 09/19/2002 | WO2002072607A2 Soluble heterodimeric cytokine receptor |
| 09/19/2002 | WO2002072602A2 Somatostatin antagonists |
| 09/19/2002 | WO2002072596A1 Steap-related protein |
| 09/19/2002 | WO2002072151A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 09/19/2002 | WO2002072149A1 Methods for reducing fat by administration of adiponectin |
| 09/19/2002 | WO2002072146A2 Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
| 09/19/2002 | WO2002072144A1 Remedies for nerve damages |
| 09/19/2002 | WO2002072138A1 Methods and materials relating to fibulin-like polypeptides and polynucleotides |
| 09/19/2002 | WO2002072137A2 Anaesthetic formulation comprising articaine |
| 09/19/2002 | WO2002072136A1 Compositions and methods for stimulating wound healing and fibroblast proliferation |
| 09/19/2002 | WO2002072135A1 LIQUID INTERFERON α PREPARATIONS FOR INJECTION AND METHOD OF STABILIZING THE SAME |
| 09/19/2002 | WO2002072134A1 Remedies for arthritis deformans and remedies for rheumatoid arthritis |
| 09/19/2002 | WO2002072133A1 Immunomodulatory properties of bip |
| 09/19/2002 | WO2002072132A1 Combinations of heparin cofactor ii agonist and platelet iib/iiia antagonist, and uses thereof |
| 09/19/2002 | WO2002072131A1 Remedies for liver diseases |
| 09/19/2002 | WO2002072130A1 Method of preventing adhesions by apoptosis of adhesion peritoneal cells |
| 09/19/2002 | WO2002072129A1 METHODS FOR REGULATING BUD-HYPHA TRANSITIONS AND cAMP LEVELS BY THE ADENYLATE CYCLASE-ASSOCIATED PROTEIN GENE, CAP1 |
| 09/19/2002 | WO2002072128A1 Cross-linked gelatin composition comprising a wetting agent |
| 09/19/2002 | WO2002072127A2 Modulation of smooth muscle cell proliferation by vegf-x or antagonists thereof |
| 09/19/2002 | WO2002072115A2 Vectors, compositions and methods for treating a vascular disorder |
| 09/19/2002 | WO2002072106A2 Combined method for treating hormono-dependent disorders with exemestane |
| 09/19/2002 | WO2002072085A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 09/19/2002 | WO2002072075A1 Oral peptide pharmaceutical dosage form and method of production |
| 09/19/2002 | WO2002072032A2 Compounds and methods for identifying, staging and treating cutaneous t-cell lymphoma |
| 09/19/2002 | WO2002072030A2 High affinity integrin polypeptides and uses thereof |
| 09/19/2002 | WO2002072026A2 In situ langerhans cell vaccine |
| 09/19/2002 | WO2002072024A2 Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto |
| 09/19/2002 | WO2002072023A2 Production of high levels of transgenic factor viii with engineered stability, and its therapeutic uses |
| 09/19/2002 | WO2002072019A2 Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
| 09/19/2002 | WO2002072016A2 Method of preventing adhesions with ifn-¿y? |
| 09/19/2002 | WO2002072005A2 Linear y-carboxyglutamate rich conotoxins |
| 09/19/2002 | WO2002071927A2 Diagnosis and treatment of skeletal degeneration conditions |
| 09/19/2002 | WO2002071874A2 Composition improving age-related physiological deficits and increasing longevity |
| 09/19/2002 | WO2002071847A1 Treatment of neurodegenerative diseases and conditions using pari antagonists |
| 09/19/2002 | WO2002071843A1 Recombinant adeno-assocaited virus-mediated gene transfer via retroductal infusion of virions |
| 09/19/2002 | WO2002071827A2 Retinoid x receptor modulators |
| 09/19/2002 | WO2002055532A3 Variant growth hormone molecules conjugated with macromolecular compounds |
| 09/19/2002 | WO2002053617B1 Linear block polymer |
| 09/19/2002 | WO2002052934A3 Pesticidal and antiparasitic compositions |
| 09/19/2002 | WO2002050119A3 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 09/19/2002 | WO2002036154A9 Procollagen (iii) propeptides and related substances for treating fibrotic diseases |
| 09/19/2002 | WO2002033119A9 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis |
| 09/19/2002 | WO2002033096A3 Regulation of human serine-threonine protein kinase |
| 09/19/2002 | WO2002033079A3 Human g-protein coupled receptor and uses thereof |
| 09/19/2002 | WO2002032940A3 Osteopontin-coated surfaces and methods of use |
| 09/19/2002 | WO2002032374A3 Methods for treating il-18 mediated disorders |
| 09/19/2002 | WO2002020805A3 Regulation of human carboxypeptidase-like enzyme |
| 09/19/2002 | WO2002018341A3 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 09/19/2002 | WO2002017949A9 Novel functions for dp214 |
| 09/19/2002 | WO2002014350A3 Peptide and peptide mimetic derivatives with integrin inhibitor properties ii |
| 09/19/2002 | WO2002012887A3 Methods and compositions for the diagnosis and treatment of brown adipose cell disorders |
| 09/19/2002 | WO2002012456A3 Ampk-related serine/threonine kinase, designated snark |
| 09/19/2002 | WO2002010379A3 Modified cea and uses thereof |
| 09/19/2002 | WO2002010192A3 Somatostatin analogues |
| 09/19/2002 | WO2002005792A9 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 09/19/2002 | WO2002004953A3 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 09/19/2002 | WO2002004487A3 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 09/19/2002 | WO2002002765A3 Chimeric promoters for controlling expression in smooth muscle cells |
| 09/19/2002 | WO2002002610A3 Secretion and trafficking molecules |
| 09/19/2002 | WO2001096374A9 32252, a human amp-binding family member and uses thereof |
| 09/19/2002 | WO2001096370A9 Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof |
| 09/19/2002 | WO2001092299A9 Adenovirus particles with mutagenized fiber proteins |
| 09/19/2002 | WO2001090185A3 Pt32 sperm protein, sperm c-yes, oocyte cytoplasmic c-yes, and uses thereof |
| 09/19/2002 | WO2001085956A3 Lipid metabolism enzymes |
| 09/19/2002 | WO2001085208A8 Molecular antigen arrays and vaccines |
| 09/19/2002 | WO2001083521A3 Reductive alkylation process on glycopeptides |
| 09/19/2002 | WO2001083514A3 Nucleic acids encoding a regulator of a g protein signaling, rgs18, and uses thereof |
| 09/19/2002 | WO2001064949A3 Diagnostics and therapeutics for glaucoma |
| 09/19/2002 | WO2001051518A3 Nucleic acids encoding human semaphorin proteins and use thereof |
| 09/19/2002 | WO2001036630A9 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
| 09/19/2002 | WO2001035899A9 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 09/19/2002 | WO2001030843A9 Ligand activated transcriptional regulator proteins |
| 09/19/2002 | WO2001025264A9 Substituted phosphinate based peptide derivatives |
| 09/19/2002 | WO2001007483A9 Prognosis and therapy of malignant diseases by antibodies which bind phosphorylated met protein |
| 09/19/2002 | WO2000071578A9 New polypeptides and their use for the rescue of fusion defective virus or retrovirus glycoproteins |
| 09/19/2002 | WO1997046589A3 Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods |
| 09/19/2002 | US20020133844 Animal model for use in the treatment of cell proliferative disorders |
| 09/19/2002 | US20020133843 Expression vector for generating animal models for use in the treatment of epilepsy, depression and hyperactivity |
| 09/19/2002 | US20020133840 Expression vector for generating animal model for use in the treatment of propagation, psychological and nervous system disorders |
| 09/19/2002 | US20020133836 Methods to identify swine genetically resistant to F18 E. coli associated diseases |
| 09/19/2002 | US20020133169 Repair of ruptured membrane by injection of naturally occurring protein in amniotic fluid sac |
| 09/19/2002 | US20020133001 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 09/19/2002 | US20020133000 Neuronal protein for use in inducing sleep and for treatment of sleep disorders |
| 09/19/2002 | US20020132996 Secretory protein-48 |
| 09/19/2002 | US20020132995 Modulation of immune response to preferential nucleotide sequences; obtain nucleotide sequence sample, insert adjusted nucleotides, administer to mammals monitor immune response |
| 09/19/2002 | US20020132994 Nucleotide sequences coding polypeptide for use in the treatment and prevention of microorganismal infections |
| 09/19/2002 | US20020132985 Removing multivalent ions from protein; obtain solution containing protein, adjust hydrogen ion concentration, diafilter solution, recover retentate |
| 09/19/2002 | US20020132984 Polypeptide for use in the treatment of neutropenia |
| 09/19/2002 | US20020132982 Complexing antihemophila factor in fluid; obtain antihemophila protein, adjust protein conformation, bind to stabilizer, monitor activity |
| 09/19/2002 | US20020132981 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/19/2002 | US20020132978 VEGF-modulated genes and methods employing them |
| 09/19/2002 | US20020132977 Polypeptide for use in the diagnosis and treatment of cancer |
| 09/19/2002 | US20020132976 Immunogenic peptides derived from prostate-specific antigen (PSA) and uses thereof |
| 09/19/2002 | US20020132973 Peptide parathyroid hormone analogs |
| 09/19/2002 | US20020132835 Treatment of Infant Respiratory Distress Syndrome or Adult Respiratory Distress Syndrome by administering a combination of a phospholipid lung surfactant with N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide |
| 09/19/2002 | US20020132788 Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
| 09/19/2002 | US20020132781 Optionally a glutathione pathway enhancing and detoxifying compound, particularly cystine |
| 09/19/2002 | US20020132779 Analogs of L-Glu-L-Trp having pharmacological activity |